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Significance of this study
What is already known about this subject?
 ► Because long-standing colonic IBD is associated 
with an increased risk of colorectal cancer 
(CRC), the current clinical recommendation is 
for interval colonoscopy for CRC surveillance.
 ► The recommended interval for CRC surveillance 
in this population ranges anywhere from 1 
to 5 years, and most often every 1–2 years, 
depending on clinical and endoscopic factors.
 ► Colonoscopic surveillance, which is  
associated with increased cost, patient 
inconvenience and small procedural risk, is of 
uncertain benefit in patients with no additional 
risk factors for CRC and well-controlled IBD  
with quiescent endoscopic disease on 
follow-up.
AbSTrACT
Objectives Surveillance colonoscopy is thought to 
prevent colorectal cancer (crc) in patients with long-
standing colonic iBD, but data regarding the frequency 
of surveillance and the findings thereof are lacking. 
Our aim was to determine whether consecutive 
negative surveillance colonoscopies adequately predict 
low neoplastic risk.
Design a multicentre, multinational database of 
patients with long-standing iBD colitis without high-risk 
features and undergoing regular crc surveillance was 
constructed. a ’negative’ surveillance colonoscopy was 
predefined as a technically adequate procedure having 
no postinflammatory polyps, no strictures, no endoscopic 
disease activity and no evidence of neoplasia; a ’positive’ 
colonoscopy was a technically adequate procedure that 
included at least one of these criteria. the primary endpoint 
was advanced colorectal neoplasia (acrn), defined as 
high-grade dysplasia or crc.
results Of 775 patients with long-standing iBD 
colitis, 44% (n=340) had >1 negative colonoscopy. 
Patients with consecutive negative surveillance 
colonoscopies were compared with those who had 
at least one positive colonoscopy. Both groups had 
similar demographics, disease-related characteristics, 
number of surveillance colonoscopies and time 
intervals between colonoscopies. no acrn occurred 
in those with consecutive negative surveillance, 
compared with an incidence rate of 0.29 to 0.76/100 
patient-years (P=0.02) in those having >1 positive 
colonoscopy on follow-up of 6.1 (P25–P75: 4.6–8.2) 
years after the index procedure.
Conclusion Within this large surveillance cohort of 
patients with colonic iBD and no additional high-risk 
features, having two consecutive negative colonoscopies 
predicted a very low risk of acrn occurrence on follow-
up. Our findings suggest that longer surveillance intervals 
in this selected population may be safe.
InTrODuCTIOn
Patients with long-standing colonic IBD are at 
an increased risk of developing colorectal cancer 
(CRC).1 2 Colonoscopic surveillance is widely 
used in these patients to prevent CRC-related 
mortality. Current guidelines use individual 
risk stratification to determine patient-spe-
cific surveillance intervals, ranging from 1 to 5 
years.3–5 The European and British guidelines 
have incorporated a low-risk category for patients 
who have no high-risk or intermediate-risk 
features—such as primary sclerosing cholangitis 
(PSC), active inflammation or prior history of 
neoplasia—after an initial screening colonos-
copy and allow for a 5-year surveillance interval 
in this selected population. This is in contrast to 
practice in North America, where there are no 
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Significance of this study
What are the new findings?
 ► Using a large tri-national and multicentre database of 
patients with confirmed colonic IBD undergoing colonoscopic 
surveillance for CRC, we demonstrated that patients without 
high-risk demographics (eg, primary sclerosing cholangitis 
(PSC), personal or family history of colorectal neoplasia), 
undergoing adequate quality-metric surveillance colonoscopy 
without high-risk findings on examination, such as active 
inflammation, stricture, postinflammatory polyps and 
dysplasia (ie, a ‘negative’ colonoscopy), had a very low risk of 
future high-grade dysplasia or CRC.
 ► Of the cohort without high-risk features like PSC, no one  
with two consecutive negative surveillance colonoscopies 
developed high-grade dysplasia or CRC on follow-up.
How might it impact on clinical practice in the foreseeable 
future?
 ► Our findings inform current surveillance guidelines 
for the IBD population and suggest that in patients 
without additional risk factors for CRC and with at least 
two consecutive surveillance examinations showing 
endoscopically quiescent disease and no high-risk features, 
an interval longer than 2 years between surveillance 
examinations may be appropriate.
 ► A longer interval would optimise the cost and resource-to-
benefit ratio of surveillance and would improve the quality 
of life for a large percentage of patients with IBD enrolled in 
surveillance.
distinct recommendations for the low-risk group, who are 
instead subjected to an every 1-year to 2-year colonoscopic 
surveillance protocol. This contributes a burden to health-
care systems in terms of costs and capacity, and to patients in 
terms of procedural risks, inconvenience and personal costs.
Several large well-designed studies in patients without IBD 
provide evidence-based guidance on the risk of CRC after 
negative investigations and inform clinical practice.6–10 For 
example, a recent study that included over 2100 average-risk 
patients found that an adequate quality-metric screening 
colonoscopy with negative results had significantly lower 
rates of adenomas or advanced neoplasms and no cancers 
at their 10-year follow-up colonoscopy, compared with 
people undergoing their first screening colonoscopy, with the 
authors concluding that a 10-year interval for CRC screening 
after a negative colonoscopy is safe in the average-risk popu-
lation.10 Furthermore, British screening colonoscopy guide-
lines suggest that after removal of sporadic adenomas, having 
two subsequent negative surveillance colonoscopies suggests 
that future examinations can be discontinued altogether.11 So 
far, data justifying longer surveillance intervals for low-risk 
patients with IBD, however, are lacking. We sought to address 
this question by using a multinational, multicentre database 
of patients with long-standing IBD colitis and no other high-
risk features undergoing colonoscopic CRC surveillance. 
The overall aim was to determine whether two consecutive 
surveillance colonoscopies that demonstrated no interme-
diate-risk to high-risk findings (according to strict criteria) 
might predict absent or low rates of advanced colorectal 
neoplasia (aCRN), defined as high-grade dysplasia (HGD) or 
CRC, during follow-up.
MeTHODS
Study population and case identification
Patients undergoing colonoscopic surveillance for IBD colitis 
between 2000 and 2015 were retrospectively identified from 
three databases: a Dutch (Netherlands, NL) database that 
included two secondary and six tertiary centres, a US database 
that included one tertiary centre and a Canadian database that 
also included one tertiary centre. Cases were identified through 
a query of the electronic health record (EHR)-linked database 
for all cases of IBD or through the individual centre’s patient 
registry.
Patient selection (inclusion and exclusion criteria)
After initial identification through the EHR query, individual 
charts were reviewed. Inclusion criteria were (1) diagnosis of 
IBD (UC, Crohn’s disease (CD), IBD undifferentiated (IBD-U)) 
with colonic involvement confirmed by pathology, (2) confirmed 
colonic disease duration of at least 8 years (referred to here-
after as ‘long-standing’), (3) enrolment in a dysplasia surveillance 
programme, (4) at least two separate colonic pathology reports 
from surveillance examinations, (5) at least left-sided disease 
extent (UC or IBD-U) or involvement of >30% of the colonic 
surface (CD or IBD-U) and (6) no aCRN prior to, or at, index 
colonoscopy during the defined study period. Exclusion criteria 
were (1) CD without colonic involvement, (2) UC or IBD-U with 
limited proctitis and CD or IBD-U with <30% colonic involve-
ment and (3) less than two surveillance colonoscopies with avail-
able pathology. So-called ‘high risk’ patients were also excluded 
if they had any of the following a priori determined factors: 
PSC, history of any dysplasia or CRC prior to, or at, index colo-
noscopy, prior history of stricture or first-degree relative with a 
history of CRC.
Date of enrolment was the date of the first surveillance colo-
noscopy within the stated study period (hereafter referred to as 
the ‘index colonoscopy’). Surveillance procedures were defined 
as colonoscopies in which either segmental random biopsies 
or chromoendoscopy were employed. We excluded subjects in 
whom the index or subsequent colonoscopy had inadequate 
bowel preparation according to the endoscopists’ overall impres-
sion and/or caecal intubation was not achieved, as these proce-
dures are considered technically insufficient for surveillance. We 
also excluded any colonoscopies that were performed for an 
indication other than surveillance, for example, medically refrac-
tory disease, or those that were performed with surveillance as 
the indication but did not employ at least segmental biopsies or 
chromoendoscopy. Thus, we only included patients who had at 
least two consecutive surveillance colonoscopies with adequate 
quality metrics, followed by at least one mode of pathological 
assessment on subsequent follow-up—either another surveil-
lance colonoscopy, a colonoscopy for medical refractory disease 
where biopsies were taken or colectomy (segmental, subtotal, 
total)—to determine whether or not there was an eventual diag-
nosis of dysplasia and/or CRC.
Any interval aCRN diagnosis, irrespective of diagnostic setting 
(e.g, colectomy), was recorded.
Data collection
The following baseline demographic and clinical data were 
abstracted: date of birth, sex, age of IBD diagnosis, IBD type 
(UC, CD or IBD-U), maximum extent of colonic disease at any 
time during follow-up, family history of CRC and diagnosis 
of PSC by endoscopic retrograde cholangiopancreatography 
(ERCP) and/or magnetic resonance cholangiopancreatography 
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Figure 1 Group allocation algorithm (index procedure). All colonoscopic procedures (positive or negative) had caecal intubation and adequate 
bowel preparation. CRC, colorectal cancer; PSC, primary sclerosing cholangitis.
Figure 2 Selection of patients and group allocation.
(MRCP). Medication exposure was defined as duration of 
use for at least 3 months according to EHR documentation 
and was recorded for 5-aminosalicylates, immunomodulators 
(azathioprine or 6-mercaptopurine) and biologics.
Details of the index surveillance colonoscopy and each subse-
quent surveillance examination were recorded, including quality of 
bowel preparation as determined by the endoscopist at the time of 
the examination (adequate (excellent or good) or inadequate (fair 
or poor), the latter of which were excluded), use of chromoen-
doscopy, most proximal colonic extent examined (with exclusion 
of those procedures where caecal intubation was not achieved), 
overall impression of endoscopic inflammation (none or remis-
sion, mildly active, moderately active, severely active), presence of 
postinflammatory polyps (‘pseudopolyps’), stricture(s) and visible 
lesions. Lesion location was categorised as left-sided if located 
distal to the splenic flexure and right-sided if located proximal 
to the splenic flexure. The number of surveillance colonoscopies, 
the time interval between examinations and the duration of active 
follow-up with the treating gastroenterologist were recorded. A 
standard data collection form was used at all centres.
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Figure 3 Incidence rate of advanced colorectal neoplasia (aCRN) on follow-up after group allocation. CRC, colorectal cancer; HGD, high-grade 
dysplasia; LGD, low-grade dysplasia; NEG, negative colonoscopy; POS, ≥1 high-risk feature on colonoscopy. Incidence rate is reported per 100 patient-
years.
Histological data
All histological diagnoses were recorded as detailed in the 
original pathology report; no specimens were re-reviewed or 
altered for the purpose of this study. Dysplasia was reported as 
indefinite (IND), low-grade (LGD) or high-grade (HGD). For 
this study, any lesion graded as LGD or higher was defined as 
neoplasia; aCRN included any HGD or CRC. IND was catego-
rised as non-neoplastic. Of note, it is routine practice at all insti-
tutions participating in this study that a specimen concerning 
for neoplasia (including indefinite dysplasia) be reviewed by two 
pathologists and consensus reached before final reporting in the 
EHR.
Stratification of index colonoscopies
Patients who met inclusion criteria were first assigned to one of 
two groups based on their initial surveillance colonoscopy within 
the studied timeframe—either the negative (NEG) index colo-
noscopy group or the positive (POS) index colonoscopy group—
and then subsequently categorised according to findings on their 
second surveillance colonoscopy, as either NEG-NEG (‘double 
negative’) if the two consecutive colonoscopies were negative 
(as defined below) or NEG-POS, POS-NEG or POS-POS if the 
index and/or consecutive colonoscopies included any of the 
positive findings as detailed.
For this study, a ‘negative’ colonoscopy was strictly defined as 
a completed surveillance colonoscopy with no postinflammatory 
polyps, no strictures, absence of any endoscopic disease activity 
and no dysplasia (figure 1). If any of these criteria was not met, 
the colonoscopy was considered ‘positive’. If neoplasia (LGD or 
higher) was identified on the surveillance procedure following 
the index procedure (‘second colonoscopy’, figure 2), this was 
recorded, but these patients were excluded from the primary 
analysis assessing the subsequent development of neoplasia 
following two surveillance procedures. If the diagnosis was LGD, 
these patients were instead allocated to the high-risk group and 
analysed separately; if the diagnosis was aCRN, these patients 
were excluded completely since the primary outcome had been 
reached (see below). As noted, patients deemed to be at high risk 
for dysplasia and CRC at the outset (eg, concomitant PSC, prior 
history of dysplasia, family history of CRC) were excluded from 
the primary analysis, but were allocated to the high-risk group 
and analysed separately (see below).
Primary and secondary outcomes
The primary outcome was occurrence of aCRN following 
consecutive surveillance colonoscopies after the index exam-
ination. Secondary outcomes included any neoplastic diagnosis 
during follow-up (ie, LGD or higher), and a diagnosis of aCRN 
following any two negative surveillance examinations during 
the follow-up period. Patients were censored at the time of 
aCRN diagnosis, colectomy, the date of the last gastroenterology 
follow-up or the end of the predetermined study interval, which-
ever occurred first.
Statistical analysis
Descriptive statistics were generated for patients meeting the 
inclusion criteria. Chi-square test was used for categorical vari-
ables and Student’s t-test for continuous variables. The primary 
and secondary outcomes were analysed using a time-to-event 
analysis and Kaplan-Meier survival curves were generated to 
compare the various groups according to their surveillance colo-
noscopy findings. The incidence rate of neoplasia and aCRN 
was reported as the number of cases per 100 patient-years of 
follow-up (pty) with 95% CI. The 25th to 75th percentiles were 
reported as P25–P75. Total follow-up time was reported as the 
time of index colonoscopy until the first censored time point. 
Because patients were grouped based on their findings of each of 
their two consecutive colonoscopies, group allocation was ulti-
mately determined at the time of the second colonoscopy; thus, 
we also reported a second follow-up interval for each of the 
analyses, which is the time from the date of the second colonos-
copy until the first censored time point. All statistical analyses 
were performed using SPSS V.22 (IBM).
Study oversight
The institutional review board for each of the participating sites 
approved the creation and analysis of a longitudinal retrospective 
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Age at index colonoscopy, years, median (P25–P75) 44 (35–53)
IBD diagnosis
  UC 474 (61.2%)
  Crohn’s colitis 280 (36.1%)
  Indeterminate colitis 21 (2.7%)
Disease duration, years, median (P25–P75) 13 (9–21)
Maximum disease extent (endoscopic)
  Extensive/pancolitis 390 (50.3%) 
  Left-sided/>30% colonic involvement 322 (41.6%) 
  Not specified 63 (8.1%) 
Medication exposure
  5-Aminosalicylate 658 (84.9%) 
  Immunomodulator 386 (52.0%) 
  Biological 176 (22.7%) 
Negative index colonoscopy* 340 (43.9%)
Duration of follow-up after index colonoscopy, years, median 
(P25–P75)
6.1 (4.6–8.2)
*Defined as a technically adequate surveillance colonoscopy with no 
postinflammatory polyps, no strictures, absence of any endoscopic disease activity 
and no evidence of neoplasia (low-grade dysplasia or higher) in either random or 
targeted biopsies










Male (%) 151 (44.4%) 212 (48.7%) 0.23 100 (42.7%) 247 (48.6%) 0.14
Age at index colonoscopy, years, median (P25–
P75)
45 (36–53) 43 (33–53) 0.17 46 (37–54) 44 (34–53) 0.12
IBD diagnosis
  Ulcerative colitis 206 (60.6%) 268 (61.6%) 0.72 140 (59.8%) 314 (61.8%) 0.87
  Crohn’s colitis 123 (36.2%) 157 (36.1%) 87 (37.2%) 180 (35.4%) 
  Indeterminate colitis 11 (3.2%) 10 (2.3%) 7 (3.0%) 14 (2.8%) 
Disease duration at index colonoscopy, years, 
median (P25–P75)
14 (9–22) 13 (9–20) 0.33 14 (9–23) 13 (9–20) 0.29
Medication exposure
  5-Aminosalicylate 278 (81.8%) 380 (87.4%) 0.03 190 (81.2%) 439 (86.4%) 0.07 
  Immunomodulator 160 (47.1%) 239 (54.9%) 0.03 110 (47.0%) 276 (54.3%) 0.06 
  Biological 54 (15.9%) 122 (28.0%) <0.01 33 (14.1%) 137 (27.0%) <0.01 
Postinflammatory polyps – 176 (40.5%) – – 167 (32.9%) – 
Endoscopic inflammation
  Remission/inactive 340 (100%) 117 (26.9%) – 234 (100%) 202 (39.8%) –
  Mild – 238 (54.7%) – 231 (45.5%) 
  Moderate – 63 (14.5%) – 59 (11.6%) 
  Severe – 17 (3.9%) – 16 (3.1%) 
Duration of follow-up, years, median (P25–P75)
  After index colonoscopy 6.3 (4.8–8.6) 6.1 (4.4–8.1) 0.12 6.3 (4.9–8.7) 6.0 (4.4–8.1) 0.05
  After second colonoscopy 3.8 (2.2–5.4) 3.5 (2.1–5.3) 0.24 4.0 (2.3–5.6) 3.4 (2.1–5.3) <0.01
Total colonoscopies during follow-up, mean 3.9 3.9 0.76 3.9 4.0 0.71
Time between index and second colonoscopy, 
median, years (P25–P75)
2.2 (1.9–3.1) 2.2 (1.6–3.0) 0.66 2.2 (1.9–3.1) 2.2 (1.7–3.0) 0.94
cohort database of patients with colonic IBD undergoing colo-
noscopy for CRC surveillance. This study was performed in 
compliance with the Health Insurance Portability and Account-
ability Act guidelines.
reSulTS
The baseline characteristics for the 775 patients with long-
standing IBD colitis undergoing colonoscopic surveillance 
meeting initial inclusion criteria (figure 3) are detailed in table 1, 
with characteristics of each of the individual cohorts from the 
NL, USA and Canada detailed in online supplementary table 
1. The cohort comprised 363 men (47%) with a median age at 
study entry of 44 (P25–P75: 35–53) years. The most frequent 
IBD type was UC (n=474; 61%) with median disease duration 
of 13 (P25–P75: 9–21) years.
The index colonoscopy (ie, first surveillance colonoscopy 
within the study period) fulfilled all predefined criteria for 
a negative examination in 340 patients (44%) with all others 
classified as positive examinations. Both groups were similar in 
terms of demographics and disease characteristics including age 
at index colonoscopy, sex, IBD type and disease duration, as well 
as the number of subsequent surveillance colonoscopies after the 
index procedure (3.9 vs 3.9, P=0.76). In general, medication 
use was higher in the groups with a positive index colonoscopy. 
The interval between the index colonoscopy and the subse-
quent surveillance examination was 2.2 years for both groups 
(P=0.66). Additional characteristics of the two groups stratified 
according to the findings on the index and subsequent surveil-
lance procedures are detailed in table 2A and B, respectively. The 
duration of follow-up for the cohort following the index surveil-
lance procedure was 6.1 (P25–P75: 4.6–8.2) years.
Primary outcome
The frequency of aCRN cases on follow-up after a negative 
index colonoscopy was 1/340 (0.3%) compared with 12/435 
(2.8%) in those with a positive index colonoscopy. Patients 
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Figure 4 Incidence rate of aCRN according to consecutive surveillance 
colonoscopic findings (double negative vs at least one positive). Log-
rank test, P=0.01. CRC, colorectal cancer; HGD, high-grade dysplasia.
were further stratified according to the findings on the subse-
quent surveillance colonoscopy (figure 2). The incidence rate of 
aCRN in those with double-negative surveillance examinations 
was 0/100pty compared with 0.29–0.76/100pty in those with at 
least one positive examination (P=0.01, log-rank test, figure 4). 
That is, no cases of aCRN developed over the follow-up period 
in those patients with a negative index colonoscopy and nega-
tive subsequent surveillance colonoscopy (NEG-NEG). Inci-
dence for the subgroups were NEG-POS 0.29/100pty (95% CI 
0.01 to 1.41), POS-NEG 0.43/100pty (95% CI 0.07 to 1.43) 
and POS-POS 0.76/100pty (95% CI 0.37 to 1.39). The time 
interval between the index surveillance colonoscopy and subse-
quent surveillance examination was the same between both the 
double-negative group and the group with at least one positive 
colonoscopy (median 2.2 years), as was the number of surveil-
lance colonoscopies performed during the follow-up period. 
The frequencies of colectomies for the subgroups (NEG-
NEG, NEG-POS, POS-NEG, POS-POS) were 8/234 (3.4%), 
6/93 (6.5%), 5/113 (4.4%) and 18/302 (6.0%), respectively 
(P=0.51). The median follow-up time following the second 
surveillance procedure for the cohort was 3.6 years (P25–P75: 
3.6–5.4 years).
Secondary outcomes
Of interest, there were 91 additional patients who had two 
consecutive negative colonoscopies at any time during the study 
period but not including the index examination closest to the 
start of the predetermined study period (for example, a patient 
with a positive colonoscopy in 2000 at enrolment (POS index 
colonoscopy) who had negative examinations according to the 
predefined criteria in 2005 and 2007). Importantly, none of 
these patients developed aCRN over the period of follow-up 
(data not shown).
Among patients in whom the index and/or subsequent surveil-
lance procedure was technically insufficient (n=257) and thus 
precluded them from the primary analysis, four cases of aCRN 
occurred during the follow-up period, with an incidence rate of 
0.41/100pty.
All four groups (NEG-NEG, NEG-POS; POS-NEG; POS-POS) 
were found to have LGD during subsequent follow-up, but there 
were no significant differences between the groups with respect 
to frequency and incidence rate (P=0.68) (figure 2).
Inclusion of high-risk patients
We performed a sensitivity analysis in which we included the 619 
patients who were excluded from the primary analysis either at 
the outset of the study because of predefined high-risk features 
(n=587)—that is, PSC, history of any dysplasia prior to, or at, 
index colonoscopy, prior history of stricture, or first-degree rela-
tive with a history of CRC (online supplementary tables 2,3)—or 
because of a diagnosis of LGD prior to their second colonoscopy 
(n=32). Only one patient developed aCRN following the index 
colonoscopy and was excluded from the analysis completely 
(figure 2). The overall rate of aCRN in this extended cohort over 
the follow-up period was 0.49/100pty. Although the overall inci-
dence rates for aCRN were higher compared with the selected 
cohort for the primary analysis, the previously observed differ-
ences in incidence rates remained significantly different (online 
supplementary figure 1). The incidence rates for the subgroups 
were NEG-NEG 0.15/100pty (95% CI 0.03 to 0.51), NEG-POS 
0.44/100pty (95% CI 0.07 to 1.45), POS-NEG 0.65/100pty 
(95% CI 0.21 to 1.56) and POS-POS 0.73 (95% CI 0.38 to 
1.27). As expected, those in this extended group who were allo-
cated to the double-negative group based on two consecutive 
negative surveillance colonoscopies had the lowest incidence 
of aCRN when compared with those with either examination 
labelled positive, although not 0/100pty as in the primary anal-
ysis that excluded this ‘high-risk’ cohort.
DISCuSSIOn
In this well-characterised, multinational and multicentre data-
base of patients with long-standing IBD colitis undergoing 
routine CRC surveillance, we found markedly low rates of 
subsequent aCRN diagnoses in patients with a negative index 
examination according to predefined criteria. The incidence 
rate of aCRN after a single negative surveillance colonoscopy 
was already low at 0.09/100pty, and this rate dropped to zero in 
those patients with two consecutive negative surveillance exam-
inations during the follow-up period. Moreover, this pattern and 
its statistical significance were also seen when we analysed the 
extended cohort that included patients with any high-risk char-
acteristics for aCRN (eg, PSC, history of any neoplasia prior to, 
or at, index colonoscopy, prior history of stricture or first-degree 
relative with a history of CRC) or a diagnosis of LGD following 
the index procedure. Our findings suggest that, at least in the 
population with long-standing IBD colitis and otherwise no 
additional high-risk features, a CRC surveillance interval longer 
than 2 years is safe following two negative colonoscopies. Our 
predetermined definition of a negative colonoscopy was strict, 
yet it was based on readily available parameters recommended 
in current guidelines.3 12
While patients with IBD colitis are considered to carry a high-
er-than-average CRC risk, estimated at 5% after 20 years disease 
duration,2 the appropriateness of the recommended intervals of 
colonoscopic surveillance in this population has been incom-
pletely investigated. Considering that the overall risk of CRC in 
IBD is decreasing over time2 13 and the sensitivity for detecting 
dysplasia is increasing due in part to technological advancements 
in neoplasia detection,14 if surveillance is maintained at overly 
frequent intervals in all patients with IBD, IBD surveillance 
programmes are at risk of becoming high-intensity/low-value 
cancer prevention strategies. European guidelines advocate a 
risk stratification model when determining appropriate surveil-
lance intervals, but recommendations are inconsistent geograph-
ically and the data corroborating such recommendations are 
limited.3 5 15 Data on incidence, test sensitivity, natural history 
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and sojourn time of precursor lesions are essential to optimise 
the current surveillance strategies.
We designed our risk stratification model for the present study 
according to current British and European guidelines, which 
recommend allocating patients undergoing IBD surveillance into 
one of three groups3 15—low, intermediate and high-risk—each 
with distinct recommended surveillance intervals. We further 
made our definition of a ‘negative’ colonoscopy strict in order 
to truly define a lower risk IBD population, but also to maximise 
use of objective measures to enhance clinical reproducibility 
and facility in a practice-based setting. Patient characteristics 
including PSC,16 17 family history of CRC18 and personal history 
of neoplasia,19 as well as endoscopic features including stric-
tures,20 inflammation,21 22 and postinflammatory polyps20 23 24 
have all been shown to increase the risk of subsequent neoplastic 
transformation in IBD colitis; thus, complete absence of these 
features was necessary to meet criteria for a negative investiga-
tion. Based on these criteria, less than 30% of patients in our 
database had high-risk demographics that necessitated yearly 
surveillance colonoscopies. That said, the risk associated with 
postinflammatory polyps may vary according to the density 
and extent of postinflammatory polyps and depends ultimately 
on how completely surveillance can still be performed. More 
research is required to understand the true risk that postinflam-
matory polyps pose, be it direct (by neoplastic transformation 
of the polyp itself) or indirect (due to hindered visualisation 
of other neoplastic polyps). While there are emerging data 
suggesting that postinflammatory polyps are not independently 
associated with an increased risk of neoplasia, we chose to err on 
the side of conservative and categorised an endoscopic finding 
of postinflammatory polyps as a positive colonoscopy. Among 
the remaining low-risk patients, over one-third had at least one 
negative surveillance colonoscopy and underscores the potential 
cost-saving and resource-saving, not to mention patient conve-
nience implications, if surveillance intensity can be downgraded 
for this select population.
The definition of a low-risk surveillance population for risk 
stratification purposes in our study also has biological credence. 
Patients without signs of previous or ongoing inflammation 
have acquired less cumulative inflammatory damage over time. 
A decreased mutational burden translates into a decreased risk 
of developing aCRN.25 Moreover, endoscopically active disease, 
strictures and postinflammatory polyps all affect visibility during 
colonoscopy and thus the sensitivity of the colonoscopy itself 
for dysplasia and CRC detection. Having two strictly defined 
negative consecutive colonoscopies with enhanced diagnostic 
sensitivity broadly reduces the likelihood of missed dysplasia 
and optimises the negative predictive value of colonoscopy in 
clinical practice.
While our data raise the questions of whether (1) we may rely 
on the ability of two consecutive negative surveillance colonosco-
pies to adequately predict sustained low aCRN risk and, accord-
ingly, (2) whether we may safely prolong surveillance intervals, 
it is important to bear two caveats in mind when interpreting 
our data. First, although we attempted to maximise follow-up 
times, we had insufficient data to look at the aCRN risk beyond 
5 years. Second, in the subgroup of patients with two consecu-
tive negative colonoscopies, LGD was nonetheless detected in 
11% of patients during follow-up, thus implying that there is still 
a role for ongoing surveillance in these patients. 
As a contextual comparison, in the non-IBD background 
population, the lifetime risk of developing CRC is approximately 
4.5%, and is subject to regional and temporal variations.26 For 
patients with IBD, the risk of CRC is broadly estimated to be 
increased by a factor of 2, although numbers vary according 
to the population studied.2 27 Nevertheless, caution should be 
exercised when comparing neoplasia outcomes between patients 
with IBD and  without IBD, particularly since the trajectory 
of dysplasia progression is, generally speaking, more rapid in 
the former and implicates nuances in the dysplasia–carcinoma 
sequence.19 Indeed, CRC screening intervals for patients without 
IBD may safely extend up to 10 years, far more prolonged than 
the currently recommended screening intervals in patients with 
long-standing IBD colitis.8 28 29
Our study has some limitations, in addition to those inherent 
to any retrospective analysis. First, although our duration of 
follow-up was sufficient for achieving our study aims, we are 
unable to reliably comment on the risk of aCRN after 5 years. 
Second, the index colonoscopy was defined as the first surveil-
lance examination within our predefined study period and thus 
may not represent the true index surveillance colonoscopy in 
patients’ IBD courses. That said, this may better represent the 
real-world scenario and enhance the applicability of our find-
ings since two negative consecutive colonoscopies may occur 
at any point during patients’ surveillance programme. Thirdly, 
because our database was strictly limited to surveillance colonos-
copies, we did not specifically investigate whether intermittent 
flares between surveillance examinations significantly affect the 
neoplasia risk. Our study was also not designed to comment on 
the optimal screening interval for this low-risk group, nor of the 
necessity of concomitant clinical remission. Lastly, because chro-
moendoscopy was not routinely available at the included insti-
tutions for most of the included study period, we were unable 
to evaluate its adjunctive role in defining a negative colonoscopy 
and subsequent neoplastic risk.
There are several strengths to our study. By predefining 
variables and strict selection criteria, we were able to combine 
three large cohorts of patients with confirmed IBD colitis from 
three different countries undergoing CRC surveillance without 
compromising detailed documentation of patients’ baseline 
demographics, disease-related characteristics, and follow-up 
colonoscopic and histological findings. In this way, we maxi-
mised generalisability, sample size and power, while still precisely 
and reliably categorised patients according to our predetermined 
criteria.
In conclusion, in this large multicentre, multinational cohort 
of well-characterised patients with IBD colitis undergoing active 
CRC surveillance, we identified that in a selected low-risk 
group, having two consecutive negative surveillance examina-
tions predicts a very low and potentially negligible risk of aCRN 
on continued follow-up. Our findings support the safety of inter-
vals greater than 2 years for these low-risk patients. While we 
believe these patients can be safely surveyed at a 5-year interval, 
the robustness of this recommendation would need to be tested 
in further longitudinal research.
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